Olink Holding AB (publ)
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OLK research report →
Range $16 – $27
Price Chart
About the company
Olink Holding AB (publ) offers a comprehensive suite of products and services tailored for life science research institutions, including academic bodies, government entities, biopharmaceutical companies, and biotechnology firms. The company's product lines include Olink Explore, which is designed to aid research in critical areas such as cardiovascular and metabolic health, oncology, neurology, and inflammation. Additionally, it features the Olink Target product line and the Olink Focus product line, the latter providing bespoke solutions for clients who have already pinpointed specific proteins or protein signatures for their studies.
- CEO
- Jon Heimer
- IPO
- 2021
- Employees
- 707
- HQ
- Uppsala, SE
Get TickerSpark's AI analysis on OLK
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.24B
- P/E
- -100.31
- Fwd P/E
- 521.60
- PEG
- 1.32
- P/S
- 19.09
- P/B
- 6.43
- EV/EBITDA
- -101.88
- Div Yield
- 0.00%
- Gross Margin
- 58.19%
- Op Margin
- -29.39%
- Net Margin
- -18.63%
- ROE
- -6.93%
- ROIC
- -7.18%
Latest fiscal year · YoY change
- Revenue
- $169.91M+21.5%
- Gross Profit
- $98.87M+4.6%
- Op Income
- $-49,940,060
- Net Income
- $-31,657,721-146.3%
- EPS
- $-0.26-136.4%
- OCF Growth
- +0.1%
- FCF Growth
- -32.9%
- 52W High
- $26.09
- 52W Low
- $14.10
- 50D MA
- $24.39
- 200D MA
- $23.55
- Beta
- 0.52
- RSI (14)
- 77
- Avg Volume
- 545.96K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Olink reiterated full-year guidance after a softer Q2, pointing to strong early demand for the newly launched Explore HT and a heavier back-half revenue pattern.· August 9, 2023
- Q2 revenue was $29.4 million, up 7% year over year on a reported and constant-currency basis.
- Adjusted EBITDA was negative $11.6 million versus negative $7.9 million a year ago; net loss was $8.3 million, or $0.07 per share.
- Explore revenue was $18.2 million, with 11 new sites added in the quarter and total sites reaching 74 by June 30.
- Management launched Explore HT in July, saying early customer response has been very positive and the pipeline is growing across biopharma, academia, and government.
- Full-year 2023 revenue guidance was reiterated at $192 million to $200 million, and management said it still expects adjusted EBITDA profitability this year.
Q2 2023 revenue was $29.4 million, up 7% year over year reported and on a constant-currency basis. Revenue included $10.5 million of kits, $15.5 million of analysis services, and $3.4 million of other revenue. Adjusted gross profit margin was 62% versus 65% in Q2 2022; kits margin was 81% versus 91%; services margin was 56% versus 58%. Adjusted EBITDA was negative $11.6 million versus negative $7.9 million a year ago, and net loss was $8.3 million, or $0.07 per share, versus a net loss of $4.8 million, or $0.04 per share, in Q2 2022. Cash ended the quarter at $150 million. For 2023, management reiterated revenue guidance of $192 million to $200 million, implying about 37% to 43% reported growth, and said it expects to return to adjusted EBITDA profitability this year. They also said kit mix should be 50% for 2023, with kit margins expected to improve sequentially in Q3 and Q4 and service margins also improving sequentially.
Jon Heimer framed the quarter around continued momentum plus a major product inflection with the July launch of Explore HT. He said the launch marks a new chapter for Olink, with much higher throughput, lower cost per data point, a smaller environmental footprint, and the same high data quality, and he described early customer reaction as remarkably strong. His tone was upbeat and confident, while acknowledging that macro headwinds and the launch contributed to a back-half weighted revenue pattern.
Oskar Hjelm emphasized that the quarter was softer on profitability but still in line with the company’s seasonal setup for the year. He pointed to $29.4 million of revenue, 62% adjusted gross margin, and negative $11.6 million of adjusted EBITDA, while noting kits revenue grew 47% to $10.5 million. He said gross margins were pressured by supplier costs, logistics, and component scrapping that should be transitory, and he expects kit margins to improve sequentially in Q3 and Q4. He also said Olink exited Q2 with $150 million in cash and intends to remain disciplined while still pursuing internal investment and external opportunities.
Analysts focused on whether the reiterated full-year guide assumed customers were pausing orders ahead of Explore HT and how much Q4 spending flush could help or hurt. Management said some orders were intentionally pushed into the second half because of HT timing and customer planning, but they would not quantify the shift; they said the pipeline and early HT reception support the guide. Questions also centered on pricing and margins for HT, with management saying HT carries about a 20% premium to Explore 3072, but lower operating cost per sample helps total experiment economics and that service margins should benefit over time from higher throughput.
The positive case from this call is that Explore HT appears to be a meaningful upgrade that customers want quickly, not a product waiting for demand. Management said the pipeline is growing, adoption is broad across regions and customer types, and the company still expects full-year revenue growth of 37% to 43% plus adjusted EBITDA profitability. The company also highlighted expanding scientific traction, including more than 1,300 peer-reviewed publications citing PEA technology.
The main risks are continued macro-driven deal friction, especially in biopharma and EMEA, and the fact that several orders slipped into the second half rather than disappearing. Gross margins fell year over year, with kits margin dropping to 81% from 91% and adjusted EBITDA still negative in Q2. Management also said it is too early to know how much HT will lift pull-through or whether the recent momentum will fully offset the softer first half.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 32.9%
- Shares Outstanding
- 124.34M
- Float Shares
- 40.95M
of shares held by institutions
3 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 785.28K | ▼ 4.62K |
Our OLK coverage
Recent articles, reports, and earnings notes.
No research on OLK yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OLK report →Verici Dx gains Olink Certified Service Provider status to expand proteomics offering
proactiveinvestors.co.uk · Aug 11
Olink® Reveal Seamlessly Connects Genomics and Proteomics, Empowering Researchers to Uncover the Dynamic Mechanisms Underlying Biology
businesswire.com · Jan 27
Notice to attend the Extra General Meeting of Olink Holding AB (publ)
globenewswire.com · Jul 11
Olink's (OLK) Acquisition by Thermo Fisher Gets UK CMA Nod
zacks.com · Jul 9
Olink Announces Receipt of CMA Clearance for Proposed Acquisition by Thermo Fisher
globenewswire.com · Jul 8
UK's competition regulator clears $3.1 bln Thermo Fisher Scientific-Olink deal
reuters.com · Jul 8
Report from the Extra General Meeting of Olink Holding AB (publ) on 5 July 2024
globenewswire.com · Jul 5
Olink® Introduces Global Network of Certified Service Providers to Accelerate Protein Biomarker Discovery
globenewswire.com · Jul 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.